Long-term safety of etanercept in psoriasis: Retrospective study focused on infections.
OBJECTIVE
Retrospective study to evaluate the incidence of infectious adverse events in patients with psoriasis treated with etanercept.


METHODS
Patients with psoriasis or psoriatic arthritis who were treated with etanercept (50 mg, administered weekly via subcutaneous injection) for ≥48 weeks were retrospectively enrolled. Patients were screened for occult infections before treatment commenced, and then every 12 months thereafter. Minor (not requiring hospitalization and/or discontinuation of treatment) and major (requiring hospitalization and/or discontinuation of treatment) infectious events were recorded.


RESULTS
The study included 50 patients. Minor infectious events included self-limiting upper respiratory tract infections (six patients), lower urinary tract infections (one patient) and recurrent herpes simplex labialis (two patients). Major infections occurred in only two cases.


CONCLUSIONS
These data support the good safety profile of etanercept in patients with psoriasis or psoriatic arthritis.
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy.
Diego
D
Orsini
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy.
Alessandra
A
Narcisi
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy.
Annalisa
A
Arcese
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy antonio.costanzo@uniroma1.it.
Antonio
A
Costanzo
Etanercept; psoriasis; psoriatic arthritis; safety; tumour necrosis factor-α
J Invest Dermatol. 2015 Nov;135(11):2641-2648
26046458
Nat Commun. 2014 Dec 03;5:5621
25470744
Expert Opin Biol Ther. 2008 Apr;8(4):491-502
18352852
Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10
17075599
World J Gastroenterol. 2014 Nov 21;20(43):16014-9
25473153
Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:9-20
25398488
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
15083780
J Drugs Dermatol. 2013 Mar;12(3):e41-5
23545925
N Engl J Med. 2009 Jul 30;361(5):496-509
19641206